ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2013

Cardiovascular Disease

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

12,168Medicare Part D Prescriptions Filled, Including Refills

Rank: 49 out of 1469

$920K Total Retail Price of All Prescriptions

Rank: 41 out of 1469

582 Patients Receiving at Least One Drug in Part D
88% Patients 65 Years and Older
46% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg 81928cdb0ebe162ff75cf405bfacadd396bf3ec84bc467b6f3e612dd63daa776 Average for
this specialty
in California
Lower avg 72b1978e1dcc0b845f89d17d692cfff7aeaf8d8bce70310d8bfc535db2daf62a

Schedule Two
Controlled Substances

3% of this provider’s 582 patients filled at least one prescription for a schedule two drug, compared to an average of 0%.

Schedule Three
Controlled Substances

12% of this provider’s 582 patients filled at least one prescription for a schedule three drug, compared to an average of 2%.

Brand Name Drugs

33% of this provider’s prescriptions were for brand-name drugs, compared to an average of 24%.

Prescription Price

$76 was the average price of a prescription from this provider, compared to $65 among peers.

Prescriptions per Patient

21 is the average number of prescriptions (including refills) per patient, compared to an average of 12.


This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

B

A benzodiazepine, or tranquilizer. More » The American Geriatrics Society says these drugs increase the risk of cognitive impairment, delirium, falls and fractures in older adults.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled with Refills Prescriptions
to 65+
Patients Recieving this Drug Category For this Prescriber For All Prescribers in
This Specialty in California
ATORVASTATIN CALCIUM 1,047 908 268 1 1
AMLODIPINE BESYLATE 640 611 150 2 3
CARVEDILOL 469 395 110 3 2
LEVOTHYROXINE SODIUM 391 354 82 4 21
FUROSEMIDE 366 337 74 5 8
SIMVASTATIN 306 278 60 6 6
METFORMIN HCL 304 242 60 7 25
ZETIA 304 270 85 7 27
OMEPRAZOLE 295 273 59 9 23
HYDROCODONE-ACETAMINOPHEN 270 210 57 S3 10 31
BENAZEPRIL HCL 262 241 51 11 26
DIOVAN 256 251* 34 12 14
POTASSIUM CHLORIDE 249 244* 48 13 18
CRESTOR 238 208 73 14 15
LOSARTAN POTASSIUM 209 204* 56 15 11
TAMSULOSIN HCL 171 151 37 16 44
WARFARIN SODIUM 168 168 38 17 9
SPIRIVA 144 133 26 18 101
ALENDRONATE SODIUM 141 141 23 19 50
PRAVASTATIN SODIUM 134 129* 28 20 19
LISINOPRIL 133 106 28 21 7
AMIODARONE HCL 129 124* 28 22 20
SPIRONOLACTONE 120 115* 24 23 22
CLOPIDOGREL 119 98 24 24 5
RAMIPRIL 119 95 20 24 35
AMLODIPINE BESYLATE-BENAZEPRIL 114 109* 23 26 74
RANEXA 108 96 20 27 33
NIASPAN 103 98* 26 28 62
ADVAIR DISKUS 100 69 18 29 77
PIOGLITAZONE HCL 93 76 24 R 30 88
XARELTO 87 82* 17 31 24
GABAPENTIN 83 78* 13 32 48
EXFORGE 82 82 13 33 89
METOPROLOL SUCCINATE 78 73* 21 34 4
KLOR-CON 10 72 67* 24 35 105
TEMAZEPAM 70 70 16 B 36 110
AVODART 69 <11 <11 37 112
MULTAQ 67 <11 <11 38 57
JANUVIA 66 52 18 39 64
AZOR 64 64 12 40 119
LORAZEPAM 63 46 13 B 41 60
CYMBALTA 62 57* 11 42 117
KLOR-CON M10 59 <11 <11 43 276
LANTUS 59 54* 17 43 107
TORSEMIDE 57 57 18 45 99
FINASTERIDE 57 52* 11 45 137
HYDROCHLOROTHIAZIDE 55 50* 14 47 16
GLIMEPIRIDE 54 <11 <11 48 63
BENICAR 54 49* 13 48 49
INSULIN SYRINGE* 52 47* 17 50 218
WELCHOL 51 46* 15 51 106
About This Data

Prescribing data from Medicare’s prescription drug benefit, known as Part D, was compiled and released by the Centers for Medicare and Medicaid Services, the federal agency that oversees the program. ProPublica combined that data with additional information released by CMS. The data for 2013 includes nearly 1.4 billion prescriptions written by 1.3 million doctors, nurses and other providers. This database lists about 410,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths of these prescriptions went to patients 65 and older; the rest were for disabled patients Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to checkup@propublica.org and we will update your information. If you have other questions about this data, send a note to checkup@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 30, 2013.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.